共 50 条
- [36] Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2388 - 2392
- [40] Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2398 - 2401